NASDAQ: ERAS

Erasca (ERAS) Stock Analysis & Forecast

Nov 13 close

$15.66−0.12 (−0.8%)

Gekko Brief

AI summaryNov 9 close

Erasca's week has been dominated by the termination of Chief Operating Officer Nicholas Chetwyn, which the company attributed to a leadership realignment. The departure sparked a stock drop of nearly 10% and prompted Pomerantz LLP, and separately Grabar Law Office, to launch investigations into potential securities fraud or breaches of fiduciary duty. Separately, Erasca and Tango Therapeutics initiated a Phase 1/2 study combining the oral PRMT5 inhibitor vopimetostat with the pan-RAS molecular glue ERAS-0015, and management is set to present at three investor conferences in November, including sessions from Guggenheim, Stifel, and Jefferies.

Shares closed at $15.61, up 8.3% on the day, sitting between the 50-day average of $15.03 and the 200-day average of $15.14. The GekkoIndex reads 56.3, placing the stock in the Neutral zone, down from a reading 5 points higher. Gekko Fair Value stands at $17.22, putting the current price 9.3% below that level.

Erasca reports earnings on 11 November 2026, just 116 days away and inside a typical 20-trading-day holding window; the last quarter showed an EPS of -0.14 versus a -0.11 estimate, with an average absolute reaction of 7.5% historically. Seasonality over the next 20 trading days has averaged -2.5% across 5 years, rising in 2 of them. Analyst coverage includes 5 buy and 2 hold ratings across 7 firms, with a consensus target of $24.11.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Erasca price vs fair value

$17.26$15.66Nov ’25May ’26Nov ’26
Close $15.66200-day averageGekko Fair Value $17.26

Erasca quick facts

Market cap
$5.48B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$0.95
Revenue, TTM
$0
Profit margin
0%
Dividend yield
—
Beta
0.65
Volume
8.53M avg 4.96M
1-year return
+490.9%
Typical daily move
±8%
Typical 20-day move
±12.5%
50-day average
$14.96
200-day average
$15.26
Next earnings
Mar 11
Shares outstanding
349.8M
52-week range
$2.46$24.28

Erasca swing-trade checklist

Erasca scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $15.66 sits between the 50-day ($14.96) and 200-day ($15.26) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    53.8, Neutral

    Reading 53.8 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    9.3% below

    Price is 9.3% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 116 days

    Next report Mar 11, 2027, 116 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −10.4% on average

    From this point in the calendar, the next 20 trading days averaged −10.4% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Erasca stock chart and price history

Erasca closed at $15.66 on Nov 13, 2026, +490.9% over the past year, inside a 52-week range of $2.46 to $24.28.

Close50-day average200-day averageVolume
Erasca share price, past year, with 50-day and 200-day moving averages and volume$5$10$20DecJan 2026FebMarAprMayJunJulAugSepOctNov15.66

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+5.3%
3 months
−14.3%
6 months
+53.1%
1 year
+490.9%
The full ERAS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ERAS in Gekko

Follow Erasca through every session

Put ERAS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ERAS in GekkoFree for 7 days. No credit card required.

About Erasca

Erasca works on medicines for cancers linked to the RAS/MAPK pathway, developing them in clinical trials rather than selling approved treatments yet. It is best known for its pipeline of experimental drugs aimed at this biological pathway, including candidates meant to treat lung cancer, colorectal cancer, leukemia, solid tumors and a form of brain cancer. These compounds are taken orally, and one is designed to cross into the central nervous system to reach tumors there.

The company's efforts center on moving these drug candidates through development toward potential commercial use. Its work targets patients with specific cancer types tied to RAS/MAPK pathway activity, including those with advanced or metastatic disease and recurrent brain tumors, rather than a broader patient population.

Erasca was founded in 2018 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker ERAS.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
erasca.com

Erasca GekkoIndex: the smart money zone

Erasca’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.8, in the Neutral zone, down 7.3 points over five sessions.

010053.8Neutral

Down 7.3 points over five sessions, from the Accumulation zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying38+0.1%−0.1%+2.9%+6.0%
Accumulation198+3.5%+6.3%+7.5%+14.1%
Neutral (current zone)396+2.1%+5.4%+13.7%+42.3%
Distribution63+2.5%+4.1%+7.8%+43.1%
Selling7Too few readings yet

Average ERAS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the ERAS price, zone by zone.Track ERAS in Gekko

Is Erasca stock overvalued? Gekko Fair Value

Erasca trades 9.3% below Gekko Fair Value of $17.26, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Erasca shares are worth, recalculated every trading day.

$17.26

Gekko Fair Value, Nov 14, 2026

9.3% Undervalued

At the end of Aug 2026 the price was 19.3% below the estimate.

Gekko Fair ValueShare price, month end
$17$16Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ERAS in Gekko

Erasca insider and Congress trading

No open-market insider purchases were filed for Erasca, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for ERAS in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every ERAS insider filing, plotted on the chart in Gekko.Open ERAS in Gekko

Congress trades last 90 days

No trades in ERAS were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for ERAS, plotted on the chart in Gekko.Open ERAS in Gekko

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds ERAS.

0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Erasca earnings: next date and track record

Erasca reports on Mar 11, 2027 (116 days away), and beat the EPS estimate in 3 of its last 8 reports.

3 of 8reports beat the EPS estimate
±7.5%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+8.3%Aug ’24−8.4%Nov ’24−8.6%May ’25+9.5%Aug ’25+7.6%Nov ’25−12.1%Mar ’26+2.6%May ’26−2.5%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 12, 2026−$0.14
est −$0.11
−25.7%——−2.5%
May 11, 2026−$0.60
est −$0.23
−160.9%——+2.6%
Mar 12, 2026−$0.10
est −$0.11
+8.3%——−12.1%
Nov 12, 2025−$0.11
est −$0.11
0.0%——+7.6%
Aug 12, 2025−$0.12
est −$0.12
0.0%——+9.5%
May 13, 2025−$0.11
est −$0.12
+8.3%——−8.6%
Nov 12, 2024−$0.11
est −$0.17
+35.3%——−8.4%
Aug 12, 2024−$0.29
est −$0.18
−61.1%——+8.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Erasca stock forecast and analyst price targets

Analysts’ average 12-month price target for Erasca is $24.11, +54.0% from the last close, from 6 firms rating the stock in the last 90 days.

$24.11consensus 12-month target, +54.0% from the last close
Low $20High $33
Buy4
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 6 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Piper SandlerBuy, maintained$22+40.5%
Nov 13H.C. WainwrightBuy, maintained$22+40.5%
Nov 13Bank of America SecuritiesHold, reiterated$20+27.7%
Oct 26Bank of America SecuritiesHold, maintained$20+27.7%
Oct 19Bank of America SecuritiesHold, maintained$20+27.7%
+13.7%average 20-day move after past Neutral readings
−10.4%average move over the next 20 trading days in the last 5 years
±8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Erasca seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Erasca averaged −10.4% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−29.1%2021−41.8%2022−6.5%2023−8.9%2024+32.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−3.4%2 of 5
Next 10 trading days−8.0%2 of 5
Next 15 trading days−6.2%2 of 5
Next 20 trading days−10.4%1 of 5
Next 30 trading days−9.7%2 of 5

For scale, ERAS’s typical 20-trading-day move in either direction is about 12.5%.

Erasca market cap and key statistics

Erasca’s market cap is $5.48B and revenue of $0 over the last twelve months.

Valuation

Market cap
$5.48B
EPS, TTM
−$0.95
Gekko Fair Value
$17.26

Trading

Volume
8.53M
Avg volume, 20 days
4.96M
52-week high
$24.28
52-week low
$2.46
Shares outstanding
349.8M

Financials

Revenue, TTM
$0
Profit margin
0%
Return on equity
-48.7%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.65
Typical daily move
±8%
Typical 20-day move
±12.5%

Erasca peers

Erasca’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Erasca stock FAQ

What is Erasca’s market cap?

Erasca’s market cap is $5.48B at the Nov 13, 2026 close of $15.66, with 349.8M shares outstanding.

What is the Erasca stock forecast?

The consensus analyst 12-month price target for Erasca is $24.11, +54.0% from the last close. Of the 6 firms that rated the stock in the last 90 days, 4 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Erasca stock overvalued or undervalued?

On Gekko’s estimate Erasca is undervalued: the Nov 13, 2026 close of $15.66 is 9.3% below Gekko Fair Value of $17.26. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Erasca report earnings next?

Erasca is expected to report on Mar 11, 2027 (116 days away). Analysts expect earnings of −$0.13 per share. Erasca beat the earnings estimate in 3 of its last 8 reports, moving 7.5% on average across the report.

What is Erasca’s 52-week high and low?

Erasca’s 52-week high is $24.28 and its 52-week low is $2.46; it closed at $15.66 on Nov 13, 2026, +490.9% over the past year.

Is Erasca stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and earnings risk), 2 as mixed (trend and gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Erasca the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.